MPR1d
Qfitlia, a Novel Treatment for Hemophilia A or B, Gets FDA Approval
Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.
Amgen gets expanded FDA label approval for Uplizna
Amgen (NASDAQ: NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted an expanded label approval ...
US FDA approves Amgen's Uplizna as first treatment for rare immune disorder
The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...
Zacks Investment Research on MSN2d
SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases
Sanofi SNY announced that the FDA has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, for the treatment of warm autoimmune hemolytic anemia (wAIHA) and ...
Fierce Pharma3d
Cellares' cell therapy factory-in-a-box scores coveted advanced manufacturing technology tag from FDA
A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s ...
US FDA insider Steele replaces Marks as top vaccine official, for now
The U.S. Food and Drug Administration said on Tuesday it had named Scott Steele as acting director of its Center for ...